Celtifib 5mg Injection

Celtifib 5mg injection contains active components called as Tirofiban HCL. It is a medication primarily used as an antiplatelet agent. This medication is typically administered to prevent or treat conditions related to abnormal blood clotting, particularly when there is a high risk of thrombosis (clot formation). It is often used in conjunction with PCI (commonly known as angioplasty) to help prevent blood clot formation during the procedure.  This medication may sometimes be used to manage thrombocytopenia, a condition characterized by low platelet counts. Individuals who have a known hypersensitivity or allergy to  Celtifib 5mg injection or any of its components should not receive this medication.  It is a potent antiplatelet medication. Therefore, it is contraindicated in patients with active bleeding disorders or active bleeding episodes.   It is generally contraindicated in patients with a history of hemorrhagic stroke, as it may increase the risk of recurrent bleeding in the brain. It is typically avoided in these individuals. Patients who have undergone major surgical procedures or experienced significant trauma within the previous six weeks may be at a higher risk of bleeding complications with this medication and may be considered contraindicated. It should be used with caution in kidney problems patients, and the dosage may need adjustment. Individuals with known bleeding disorders or conditions that make them prone to bleeding, such as hemophilia or von Willebrand disease, should generally not receive this medication. It may increase the risk of bleeding in the brain, so it is typically contraindicated in patients with known intracranial neoplasms (tumors) or aneurysms. It can be used in elderly patients but with caution, as they may be more prone to bleeding due to age-related changes in the body.  Celtifib 5mg injection is typically not used in children, as its safety and efficacy in pediatric populations have yet to be well established.